The honest bottom line is that PT-141 (bremelanotide) has a real but small effect on self-reported sexual desire and desire-related distress in one narrow group, premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), and no demonstrated effect on how often satisfying sexual activity actually happens. That reading rests almost entirely on two identically designed phase 3 trials, so confidence is highest for that single indication and thin everywhere beyond it.
Across the two RECONNECT phase 3 trials, bremelanotide produced statistically significant but modest placebo-adjusted gains of roughly 0.3 points on both self-reported desire and distress, with no significant increase in the number of satisfying sexual events.
RECONNECT was built as two structurally identical studies, Study 301 and Study 302, each randomized, double-blind, and placebo-controlled across a 24-week core period before an open-label extension. Running two independent, adequately powered trials rather than one reflects the regulatory expectation that a positive HSDD result be replicated before approval.
RECONNECT's two identical randomized, double-blind, placebo-controlled trials enrolled premenopausal women with acquired, generalized HSDD and were judged on two co-primary endpoints, the FSFI desire domain and FSDS-DAO item 13 for desire-related distress, across a 24-week controlled period.
The placebo-adjusted desire improvement was small, on the order of 0.3 points, measured on a subscale derived from just two questions and scored in the low single digits. Significance was reached in pooled and individual analyses, but on an instrument that registers only a few tenths near the bottom of its range, statistical significance is not the same as a change a patient would obviously perceive.
| FSFI desire domain | Bremelanotide | Placebo |
|---|---|---|
| Mean change from baseline | ~0.35 points | ~0.05 to 0.1 points |
| Two-item subscale range | low single digits | low single digits |
| Significance vs placebo | reached | reference arm |
The placebo-adjusted improvement on the FSFI desire domain was roughly 0.3 points, with bremelanotide arms gaining about 0.35 points and placebo arms 0.05 to 0.1 points, a significant but small shift on a two-item subscale scored in the low single digits.
The single most consequential result here is a negative one: bremelanotide did not significantly raise the number of satisfying sexual events over placebo, even though both subjective co-primaries moved. Because the event count is a behaviorally anchored measure of what actually happened rather than a rated internal state, its flatness is the strongest reason the record supports calling the drug's effectiveness modest.
Bremelanotide showed no statistically significant increase in the number of satisfying sexual events versus placebo, a secondary endpoint whose null result stands against the two positive subjective co-primaries and underlies the modest-effectiveness reading.
Responder analyses, which sort each participant as a responder or not against a preset threshold of meaningful improvement, showed only a minority of treated women crossing the bar and a narrow margin over placebo. That figure matters more than the mean-change numbers, because an average can be pulled up by a few strong responders while most participants change little.
In RECONNECT's responder analyses roughly a quarter of treated women met the predefined threshold for meaningful improvement versus a lower placebo fraction, leaving a between-group difference in the low double-digit percentage points and an unfavorable number needed to treat.
Across the roughly year-long open-label extension the small controlled-phase benefit appeared broadly maintained, neither amplifying with longer exposure nor clearly wearing off. The catch is that an open-label extension carries no concurrent placebo arm, so any stability observed cannot be pinned on the drug with confidence.
Open-label extension data out to about a year suggested the modest desire and distress benefit was maintained rather than growing, but with no concurrent placebo arm and a self-selected population it is weak, hypothesis-consistent support rather than proof of durable effectiveness.
Set side by side, bremelanotide and flibanserin land in the same small effect-size neighborhood on the core HSDD endpoints, which says more about the ceiling of current low-desire pharmacotherapy than about either drug outclassing the other. No adequately powered head-to-head trial exists, so the comparison rests on cross-trial and meta-analytic inference that cannot fully control for population and design differences.
| Criteria | Bremelanotide | Flibanserin |
|---|---|---|
| Dosing | As-needed subcutaneous injection | Daily oral, chronic |
| Mechanism | Melanocortin-receptor agonist | Serotonin, dopamine, norepinephrine acting |
| Effect on desire and distress | Small over placebo | Similarly small over placebo |
| Main tolerability flag | Prominent nausea | Sedation and alcohol interaction |
Cross-trial and meta-analytic comparison places bremelanotide and flibanserin in the same modest effect-size range on desire and distress, so the choice between the as-needed subcutaneous melanocortin agonist and the daily oral central agent turns on tolerability, dosing, and interaction profile rather than any decisive efficacy difference.
Any honest appraisal has to foreground how fragile the foundation is under the small measured effect. Dropout was heavy and nausea-driven, both co-primaries are self-reported, and the studied population was narrow, and each of these caps how far the finding travels.
The effectiveness evidence rests on two self-report co-primary endpoints in a narrow premenopausal HSDD population, with substantial nausea-driven dropout, likely partial unblinding from bremelanotide's side effects, a 24-week controlled window, and industry sponsorship all constraining how strongly the modest effect can be claimed.
Outside the approved premenopausal-HSDD indication the effectiveness evidence is markedly weaker and older, and it should be read as exploratory rather than established. It establishes biological plausibility for broader sexual-function effects but not reliable proof beyond the studied population.
Outside premenopausal HSDD the effectiveness evidence is limited to older, small, mechanistic studies, including a discontinued intranasal program in men with erectile dysfunction and early-phase arousal signals in women, none of which amounts to reliable proof of efficacy beyond the approved population.
Educational use only. This article describes what the published scientific and clinical literature reports about PT-141 (bremelanotide). It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
